TLN-372 for advanced KRAS-mutant solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called TLN-372 for people with advanced solid tumors that have a KRAS mutation. It aims to see if the drug is safe and effective for these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor with a KRAS mutation that is advanced or has spread.
- Your cancer must be measurable on scans.
- You should be able to perform daily activities with little or no help (ECOG score 0 or 1).
- Your organs must function well enough (checked by blood tests).
- You cannot have active or past brain metastases or other central nervous system involvement.
- You cannot have had major surgery or serious injury in the last 4 weeks, or have significant heart disease, uncontrolled infections, or other conditions that raise safety risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
This trial tests an experimental drug called LT-010391 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The drug is designed to target this mutation, and the study aims to see if it can help when standard treatments are no longer working.
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
This trial tests a combination of three drugs for lung cancer with a KRAS mutation. The drugs may shrink or slow the cancer, and one of them helps your immune system fight the cancer.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Hear when a new KRAS Mutant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.